Method to reduce or inhibit the progression of fatigue level in patients with Multiple Sclerosis and to provide neuroprotection laquinimod which comprises administering orally or a Salt thereof； laquinimod to reduce the level of fatigue, improve the functional State and deliver neuropro Protection in multiple sclerosis.
The subject invention provides methods for reducing or inhibiting progression of the level of fatigue in a multiple sclerosis human patient, for improving or inhibiting deterioration of the functional status of a multiple sclerosis human patient, and for improving or inhibiting deterioration of the general health of a multiple sclerosis human patient, comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a method for providing neuroprotection to a human subject, the method comprising orally administering to the human subject laquinimod or a pharmaceutically acceptable salt thereof.USO DE LAQUINIMOD PARA PREPARAR UN MEDICAMENTO ÚTIL PARA REDUCIR O INHIBIR LA PROGRESIÓN DEL NIVEL DE FATIGA, MEJORAR O INHIBIR EL DETERIORO DEL ESTADO FUNCIONAL, MEJORAR O INHIBIR EL DETERIORO DE LA SALUD GENERAL Y PROPORCIONAR NEUROPROTECCIÓN EN UN SUJETO HUMANO CON ESCLEROSIS MÚLTIPLE.
